1
Clinical Trials associated with HBI-2438A Phase 1, Open Label, Dose Escalation of HBI-2438 in Patients With Advanced Malignant Solid Tumors Harboring KRAS G12C Mutation
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
100 Clinical Results associated with HBI-2438
100 Translational Medicine associated with HBI-2438
100 Patents (Medical) associated with HBI-2438
100 Deals associated with HBI-2438